A selective advantage for cystic fibrosis carriers.
Lewis
L G
LG
Children's Hospital Research Foundation, University of Cincinnati, Ohio, USA.
Cohen
M B
MB
D000328:Adult; D000818:Animals; D001427:Bacterial Toxins / Q000378:metabolism; D002712:Chlorides / Q000378:metabolism; D002772:Cholera Toxin / Q000494:pharmacology; D003106:Colon / Q000378:metabolism*; D003550:Cystic Fibrosis / Q000235:genetics* / Q000378:metabolism*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D003967:Diarrhea / Q000276:immunology*; D004195:Disease Models, Animal; D004768:Enterotoxins / Q000378:metabolism; D029968:Escherichia coli Proteins; D006579:Heterozygote; D006801:Humans; D007113:Immunity, Innate; D051379:Mice
D001427:Bacterial Toxins; C505032:CFTR protein, human; D002712:Chlorides; D004768:Enterotoxins; D029968:Escherichia coli Proteins; C034151:heat stable toxin (E coli); D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D002772:Cholera Toxin